Pharmacy & Therapeutics - February 2008 - (Page 103)

Antifibrinolytic Therapy in Cardiothoracic Surgery Table 2 Detailed Study Results, continued Aminocaproic Acid, CTS Cases ARF + ACEI (584.X as secondary Dx + major or extreme SOI) Cases ARF + ACEI + hemodialysis + major or extreme SOI All cases hemodialysis + ACEI (Px = 39.95, and not Dx V541 or V560) Tranfusion/blood component counts Transfusion/blood (major or extreme SOI) Transfusion/blood (all SOI) Total ACEI cases ACEI preoperative drug ACEI same day drug ACEI postoperative drug Cases CABG (36.1x) CABG + pump (39.61) Cases CABG off pump CABG + pump + ARF + hemodialysis CABG + pump + hemodialysis CABG + pump + ARF CABG + pump + postoperative stroke Mortality (CABG + pump) CABG + off pump + ARF + hemodialysis CABG + off pump + hemodialysis CABG + off pump + ARF CABG + off pump + postoperative stroke mortality (CABG + off pump) Postoperative Complications (All Cases) Postoperative stroke Aspiration pneumonia Postoperative GI hemorrhage or ulceration Postoperative urinary tract complication Cellulitis or decubitus ulcer Septicemia Reopening of surgical site Mechanical complications due to device or implant Miscellaneous complications Central or peripheral nervous system Postoperative AMI Postoperative infections not pneumonia/wound Procedure-related perforations or lacerations Postoperative coma or stupor Postoperative pneumonia Postoperative physiological and metabolic derangements Venous thrombosis/pulmonary embolism Wound infection Post-procedure hemorrhage or hematoma Other complications of procedures 277 32 108 8,675 1,990 3,858 4,345 1,036 1,358 1,951 7,064 6,113 951 47 138 353 90 135 5 31 54 8 11 150 59 58 24 54 84 163 307 242 10 2 40 120 9 186 18 117 165 608 1,614 % 6.4 0.7 1.1 89.0 46.2 39.6 44.6 10.6 13.9 20.0 72.4 86.5 13.5 0.8 2.3 5.8 1.5 2.2 0.5 3.3 5.7 0.8 1.2 1.5 0.6 0.6 0.2 0.6 0.9 1.7 3.1 2.5 0.1 0.0 0.4 1.2 0.1 1.9 0.2 1.2 1.7 6.2 16.6 Aprotinin, CTS % 302 74 172 5,371 1,720 2,747 3,050 606 700 1,744 3,066 2,690 376 92 195 322 51 142 10 27 29 6 14 147 54 55 19 68 54 153 347 180 14 0 51 121 13 155 16 154 122 426 1075 7.5 1.8 2.5 78.4 42.6 40.1 44.5 8.8 10.2 25.4 44.7 87.7 12.3 3.4 7.2 12.0 1.9 5.3 2.7 7.2 7.7 1.6 3.7 2.1 0.8 0.8 0.3 1.0 0.8 2.2 5.1 2.6 0.2 0.0 0.7 1.8 0.2 2.3 0.2 2.2 1.8 6.2 15.7 Controls, CTS % 1,188 136 464 9,182 4,200 6,451 15,594 6.4 0.7 1.0 19.9 22.6 14.0 33.8 6,879 4,623 2,256 66 159 358 46 142 16 67 128 11 50 244 514 368 108 238 370 318 1,845 760 71 63 384 569 34 524 92 1,085 381 1,874 3,956 14.9 67.2 32.8 1.4 3.4 7.7 1.0 3.1 0.7 3.0 5.7 0.5 2.2 0.5 1.1 0.8 0.2 0.5 0.8 0.7 4.0 1.6 0.2 0.1 0.8 1.2 0.1 1.1 0.2 2.4 0.8 4.1 8.6 Vol. 33 No. 2 • February 2008 • P&T® 103

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - February 2008

Pharmacy & Therapeutics - February 2008 Contents Editorial Medication Errors Prescription: Washington The Language of (Forgive Us) Change, As P&T Enters the Digital Age New Drugs/Drug News/New Medical Devices Drug Forecast Use and Outcomes of Antifibrinolytic Therapy in Patients Undergoing Cardiothoracic Surgery at 20 Academic Medical Centers in the United States Evaluation of the Management of Acute Venous Thromboembolism and Its Outcomes: One Institution's Experience American Society of Hematology, 49th Annual Meeting Pharmaceutical Approval Update

Pharmacy & Therapeutics - February 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.